Korea’s Daewoong Pharmaceutical Joins With Turkey’s Abdi Ibrahim On Renal, Foot Ulcer Treatments
This article was originally published in PharmAsia News
Executive Summary
South Korean drug companies are looking to make inroads into emerging markets through a combination of distribution deals, and Daewoong Pharmaceutical has made its move through a deal with Turkey’s leading drug company.
You may also be interested in...
Merck Turns Again To Daewoong For Co-promotion In South Korea
SEOUL - Merck & Co. Inc. signed a co-promotion deal with Korea's Daewoong Pharmaceutical Co. Ltd. to sell Merck's Vytorin (ezetimibe/simvastatin) in Korea, adding to the companies' similar agreements for Fosamax (alendronate) and Januvia (sitagliptin), which have been sold in Korea since 2008
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.